tbuckley/cabot-search huggingface dataset:
Case Studies in Social Medicine — Attending to Structural Forces in Clinical Practice
Authors: Scott D. Stonington, Seth M. Holmes, Helena Hansen, Jeremy A. Greene, Keith A. Wailoo, Debra Malina, Stephen Morrissey, Paul E. Farmer, Michael G. Marmot
Journal: New England Journal of Medicine (2018)

Our new Case Studies in Social Medicine series highlights the importance of social concepts and context to clinical medicine. Articles in the series will discuss clinical cases and translate social medicine tools for use in education, clinical practice, and health system planning.
SAT0385 Multiple infection is independently related to death in adult patients with hemophagocytic syndrome: etiopathogenically-driven multivariate analysis in 151 patients
Authors: S. Retamozo, P. Brito-Zerón, B. Kostov, P. Moral-Moral, A. Martínez-Zapico, C. Díaz-Pedroche, G. Fraile, P. Pérez-Guerrero, E. Fonseca, A. Robles, M. Vaquero-Herrero, M.A. Calvo, M.J. Forner, C. Morcillo, J. Larrañaga, M. Rodriguez-Carballeira, M. Ruiz-Muñoz, R. Hurtado-García, S. Prieto-González, A. Aljibe Aguilar, L. Caminal-Montero, P. Hernández-Jiménez, C. Rodríguez Fernández, P. Castro, V. Morell Massó, A. Flores-Chavez, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To characterise the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically-guided multivariate model. <h3>Methods</h3> The HLH Study Group of the Spanish Group of Autoimmune Diseases (GEAS) was formed in 2013 with the aim of collecting a large series of Spanish adult patients with HLH with substantial experience in the management of patients with systemic diseases. By October 2017, the database included 151 consecutive patients who fulfilled at least 5 of the 8 criteria proposed by the Histiocytosis Society in 2004. <h3>Results</h3> The cohort consisted of 151 patients (91 male, mean age 51.4 years). After a mean follow-up of 17 months, 80 (53%) patients died. With respect to the HLH-dependent variables, adenopathies (HR 0.63, p=0.040), low platelets (HR 3.39, p=0.008), leukopenia (HR 1.81, p=0.047), severe hyponatremia (HR 1.61, p=0.042), disseminated intravascular coagulation (HR 1.87, p=0.034), bacterial infection (HR 1.99, p=0.025), mixed microbiological infections (HR 3.42, p=0.008) and &gt;1 infectious trigger (HR 2.95, p=0.003) were associated with death. Time-to-event analyses for death identified a worse survival curve for patients with neoplasia (p&lt;0.001), mixed microbiological (p=0.019) and &gt;1 (p=0.011) infections and glucocorticoid monotherapy (p=0.021). After adjusting for confounding variables, platelets&lt;100,000/mm3 (HR 2.64), severe hyponatremia (HR 1.88),&gt;1 infectious trigger (HR 3.43) and mixed microbiological infection (HR 2.96) remained significant. Multivariate Cox proportional hazards regression analysis identified &gt;1 infectious trigger (HR 2.60, 95% CI 1.16 to 5.84) as the only variable independently associated with death. <h3>Conclusions</h3> The mortality rate of adult patients diagnosed with HLH exceeds 50%. Infection with &gt;1 microbiological agent was the only independent variable associated with mortality irrespective of the underlying disease, epidemiological profile, clinical presentation and therapeutic management. <h3>Disclosure of Interest</h3> None declared
Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)
Authors: Kelly J. Norsworthy, Flora Mulkey, Ashley F. Ward, Donna Przepiorka, Albert B. Deisseroth, Ann T. Farrell, Richard Pazdur
Journal: Blood (2018)
Antimicrobial prescribing and infections in long-term care facilities (LTCF): a multilevel analysis of the HALT 2016 study, Ireland, 2017
Authors: M Tandan, K Burns, H Murphy, S Hennessy, M Cormican, A Vellinga
Journal: Eurosurveillance (2018)

Background The 2016 point prevalence survey (PPS) of healthcare-associated infections (HAI) and antimicrobial use (AMU) in Irish long-term care facilities (LTCF) (HALT) showed a 9.8% AMU and 4.4% HAI prevalence, based on aggregated data analysis. Aim Our aim was to identify institutional and resident risk factors of AMU and HAI. Methods HALT 2016 gathered information using institutional and resident questionnaires, for residents who met the surveillance definition of active HAI and/or AMU, limiting analysis to the aggregated institutional level. In January 2017, we requested additional data on age, sex, urinary catheter use and disorientation of current residents from HALT 2016 LTCF and matched to 2016 HALT data. Results Of 224 HALT 2016 LTCF, 80 provided additional information on 3,816 residents; prevalence of AMU was 10.6% and HAI was 4.7%. Presence of a coordinating physician (Odds ratio (OR): 0.3; 95% confidence interval (CI): 0.2–0.6), antimicrobial stewardship committee (OR: 0.2; 95%; CI: 0.1–0.6), healthcare assistants (OR: 0.9; 95% CI: 0.9–1.0), antimicrobial consumption feedback (OR: 0.3; 95% CI: 0.1–0.6) and medical care by personal general practitioner (OR: 0.6; 95% CI: 0.7–1.0) were associated with less AMU and feedback on surveillance of infection prevention and control (IPC) practices (OR: 0.6; 95% CI: 0.3–1.0) with less HAI. AMU and HAI varied significantly between LTCF. Conclusions Multilevel modelling identified significant inter-facility variation, as well as institutional factors associated with AMU and HAI. An antimicrobial stewardship committee linked with feedback on IPC and prescribing was associated with reduced AMU and HAI.
Abstract 14232: Progression of Native Coronary Artery Disease Measured by Intravascular Ultrasound: Systematic Review and Meta-Analysis
Authors: Bruno R Nascimento, Marcos Roberto de Sousa, Fábio N Demarqui, Daniel Chamie, Milena S Marcolino, Giuseppe Biondi-Zoccai, Eric Boersma, Antônio Luiz P Ribeiro, Marco Aurélio A Costa
Journal: Circulation (2013)

Introduction: Much effort has been made to understand the mechanisms of coronary artery disease (CAD), and to develop therapies to prevent disease progression. Systematic analysis of intravascular ...
Professional burnout among physicians and nurses in Asian intensive care units: a multinational survey
Authors: Kay Choong See, Ming Yan Zhao, Emiko Nakataki, Kaweesak Chittawatanarat, Wen-Feng Fang, Mohammad Omar Faruq, Bambang Wahjuprajitno, Yaseen M. Arabi, Wai Tat Wong, Jigeeshu V. Divatia, Jose Emmanuel Palo, Babu Raja Shrestha, Khalid M. K. Nafees, Nguyen Gia Binh, Hussain Nasser Al Rahma, Khamsay Detleuxay, Venetia Ong, Jason Phua
Journal: Intensive Care Medicine (2018)
Association of Prenatal Exposures of Polybrominated Diphenyl Ethers With Hypospadias—Reply
Authors: Gideon Koren, Katarina Aleksa
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Impact of Prophylactic Antiviral Therapy on Clinical Outcomes of Hepatitis B Virus Surface Antigen Positive Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy
Authors: Nobuhiko Yamauchi, Dai Maruyama, Ilseung Choi, Yoshiko Atsuta, Hirotaka Takasaki, Kazuho Miyashita, Yukiyoshi Moriuchi, Hideki Tsujimura, Nobuko Kubota, Go Yamamoto, Tadahiko Igarashi, Koji Izutsu, Shinichiro Yoshida, Kensuke Kojima, Toshiki Uchida, Yoshiko Inoue, Norifumi Tsukamoto, Eiichi Ohtsuka, Sachiko Suzuki, Yoko Inaguma, Satoshi Ichikawa, Hiroshi Gomyo, Yoko Ushijima, Kisato Nosaka, Mio Kurata, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami, Shigeru Kusumoto
Journal: Blood (2018)
Validity of the qSOFA Score in Low- and Middle-Income Countries—Reply
Authors: Kristina E. Rudd, Christopher W. Seymour, Derek C. Angus
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome
Authors: E. William St.Clair, Alan N. Baer, Chungwen Wei, Ghaith Noaiseh, Anne Parke, Andreea Coca, Tammy O. Utset, Mark C. Genovese, Daniel J. Wallace, James McNamara, Karen Boyle, Lynette Keyes‐Elstein, Jeffrey L. Browning, Nathalie Franchimont, Kira Smith, Joel M. Guthridge, Ignacio Sanz, Judith A. James
Journal: Arthritis & Rheumatology (2018)

Objective To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β receptor IgG fusion protein ( LT βR‐Ig), for the treatment of primary Sjögren's syndrome ( SS ), and to explore the possible mechanisms of action of this treatment. Methods In this multicenter trial, 52 patients with primary SS were randomized in a 2:1 ratio to receive subcutaneous injections of 100 mg of baminercept every week for 24 weeks or matching placebo. The primary end point was the change between screening and week 24 in the stimulated whole salivary flow ( SWSF ) rate. Secondary end points included the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index ( ESSDAI ), as well as measurements of select chemokines and cytokines and enumeration of peripheral blood B and T cell subsets. Results The change from baseline to week 24 in the SWSF rate was not significantly different between the baminercept and placebo treatment groups (baseline‐adjusted mean change −0.01 versus 0.07 ml/minute; P = 0.332). The change in the ESSDAI during treatment was also not significantly different between the treatment groups (baseline‐adjusted mean change −1.23 versus −0.15; P = 0.104). Although the incidence of adverse events was similar between the treatment groups, baminercept therapy was associated with a higher incidence of liver toxicity, including 2 serious adverse events. Baminercept also produced a significant decrease in plasma levels of CXCL 13 and significant changes in the number of circulating B and T cells, consistent with its known inhibitory effects on LT βR signaling. Conclusion In this trial, treatment with baminercept failed to significantly improve glandular and extraglandular disease in patients with primary SS , despite evidence from mechanistic studies showing that it blocks LT βR signaling.
Abstract 21150: Surgical Treatment of Asymptomatic Severe Aortic Stenosis: Impact of Surgical Timing on Long-Term Survival
Authors: Ho Jin Kim, Joon Bum Kim, Sung-Ho Jung, Suk Jung Choo, Cheol Hyun Chung, Jae Won Lee
Journal: Circulation (2017)

Introduction: Aortic valve (AV) replacement (AVR) is regarded as the only effective treatment for severe aortic stenosis (AS). The current guidelines, however, agree with watchful waiting in asymptomatic AS patients with normal left ventricular (LV) function. Hypothesis: This study aims to assess the hypothesis that timely surgical intervention is associated with the improved long-term survival in asymptomatic severe AS patients. Methods: Between 2000 and 2015 in our institution, we identified 505 patients (aged 63.9±13.1 years, 252 females) having asymptomatic severe AS (aortic valve area [AVA] ≤ 1.0cm 2 , peak trans-AV velocity [V max ] ≥ 4.0m/s or mean AV pressure gradient [PG] ≥ 40mmHg) with preserved LV function (ejection fraction ≥ 50%). Among them, very severe AS (AVA ≤ 0.6cm 2 , V max ≥ 5.0m/s or mean PG ≥ 60mmHg) was found in 152 (29.9%) patients. AVR was performed in 231 (45.7%) patients within 3 months after diagnosis (n=145) or during follow-up (n=86) thereafter either by surgical AVR (n=214) or by trans-catheter AVR (n=17). Time-varying Cox-proportional hazard models were used to determine the impact of surgical therapy on survival outcomes. Results: During a median follow-up of 58.3 months (Q1-Q3, 29.6-104.6 months), 163 (32.3%) patients died. On time-varying Cox-hazard models, surgical therapy was associated with a significant risk reduction in overall death (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.43-0.94; P=0.022) after adjusting with 32 significant risk factors for mortality. Survival benefits by AVR were consistently demonstrated in most risk subgroups of patients based on ages, severity of AS and the morphology of the AV (bicuspid) (Figure). Conclusions: Timely AVR in asymptomatic severe AS patients resulted in marked survival benefits. These study results may suggest that early robust recruitment for surgical therapy may be warranted in asymptomatic severe AS patients before developing ventricular deterioration or onset of symptoms.
Guidelines on Glycemic Targets for Persons With Type 2 Diabetes—Reply
Authors: Elizabeth L. Tung, Andrew M. Davis, Neda Laiteerapong
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Microbial Metabolite Butyrate Stimulates Bone Formation via T Regulatory Cell-Mediated Regulation of WNT10B Expression
Authors: Abdul Malik Tyagi, Mingcan Yu, Trevor M. Darby, Chiara Vaccaro, Jau-Yi Li, Joshua A. Owens, Emory Hsu, Jonathan Adams, M. Neale Weitzmann, Rheinallt M. Jones, Roberto Pacifici
Journal: Immunity (2018)

Nutritional supplementation with probiotics can prevent pathologic bone loss. Here we examined the impact of supplementation with Lactobacillus rhamnosus GG (LGG) on bone homeostasis in eugonadic young mice. Micro-computed tomography revealed that LGG increased trabecular bone volume in mice, which was due to increased bone formation. Butyrate produced in the gut following LGG ingestion, or butyrate fed directly to germ-free mice, induced the expansion of intestinal and bone marrow (BM) regulatory T (Treg) cells. Interaction of BM CD8
Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: A prospective clinical trial
Authors: X. Hua, L. Chen, Q. Zhu, W. Hu, C. Lin, Z. Long, W. Wen, X. Sun, Z. Lu, Q. Chen, D. Luo, R. Sun, H. Mo, L. Tang, W. Zhang, Z. He, H. Mai, H. Lin, L. Guo
Journal: Annals of Oncology (2018)
Health-care professional and parental views and experiences of implementing infant feeding interventions: a qualitative evidence synthesis
Authors: Elaine Toomey, Molly Byrne, Catherine Houghton, Colette Kelly, Karen Matvienko-Sikar, Jenny McSharry, Michelle Queally, Edel Doherty, Catherine B Hayes, Marita Hennessy, Sheena McHugh, Patricia M Kearney, Caroline Heary
Journal: The Lancet (2018)
Pfizer could owe NHS £500m for extending pregabalin patent for pain
Authors: Nigel Hawkes
Journal: BMJ (2018)

The UK Supreme Court has thrown out an appeal by the drug company Pfizer over its blockbuster drug pregabalin (Lyrica).

The court’s ruling that Pfizer’s subsidiary Warner-Lambert was not entitled to a patent that it used to discourage competition from generic manufacturers and to extend the life of branded pregabalin for two years will have important implications for the drug industry and for the NHS, which may be able to claim back from Pfizer more than £500m that it would have saved if the company had not sought to obstruct the cheaper generic drugs.

Pregabalin was originally licensed for epilepsy, with the patent due to run out in 2013. Pfizer had meanwhile obtained a secondary patent, valid beyond the life of the original one, covering neuropathic pain. This represented a larger market, and the drug became a big success, with annual sales of $5bn.

As the expiry …
Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India
Authors: A. Anand, L.A. Jacob, K.C. Lakshmaiah, K. Govind Babu, D. Lokanatha, M.C. Suresh Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, S.C. Saldanha, G. Giri, R. Patidar, V. Asati, R. Chethan, T. Chaudhuri, D. Koppaka, D. Panwar, R.V. Kumar
Journal: Annals of Oncology (2018)
Ten things you should know about transposable elements
Authors: Guillaume Bourque, Kathleen H. Burns, Mary Gehring, Vera Gorbunova, Andrei Seluanov, Molly Hammell, Michaël Imbeault, Zsuzsanna Izsvák, Henry L. Levin, Todd S. Macfarlan, Dixie L. Mager, Cédric Feschotte
Journal: Genome biology (2018)

Transposable elements (TEs) are major components of eukaryotic genomes. However, the extent of their impact on genome evolution, function, and disease remain a matter of intense interrogation. The rise of genomics and large-scale functional assays has shed new light on the multi-faceted activities of TEs and implies that they should no longer be marginalized. Here, we introduce the fundamental properties of TEs and their complex interactions with their cellular environment, which are crucial to understanding their impact and manifold consequences for organismal biology. While we draw examples primarily from mammalian systems, the core concepts outlined here are relevant to a broad range of organisms.
Better Outcome in Children Compared to AYAs and Young Adults after Allogeneic HSCT for AML: A Multicenter Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM -TC)
Authors: Cecile Pochon, Marie Y Detrait, Jean-Hugues Dalle, Gerard Michel, Mauricette Michallet, Yves Bertrand, Didier Blaise, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Mohamad Mohty, Noel-Jean Milpied, Patrice Chevallier, Ali Bazarbachi, Yves Chalandon, Yves Beguin, Stephanie Ngoc Nguyen, Regis Peffault De Latour, Eliane Albuisson, Marie Thérèse Rubio
Journal: Blood (2018)
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
Authors: M. Oliva, A. Spreafico, M. Taberna, L. Alemany, B. Coburn, R. Mesia, L.L. Siu
Journal: Annals of Oncology (2018)

Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and are currently being evaluated in various disease settings. However, despite the gain in overall survival seen in some of the clinical trials, the majority of patients display primary resistance and do not benefit from these agents. Taking into consideration the potentially severe immune-related toxicities and their high cost, the search for predictive biomarkers of response is crucial. Besides Programmed death ligand-1 (PD-L1) expression, other biomarkers such as immune infiltration, tumor mutational burden or immune-gene expression profiling have been explored, but none of them has been validated in this disease. Among these, the microbiota has recently garnered tremendous interest since it has proven to influence the efficacy of PD-1 blockade in some tumor types. With the accumulating evidence on the effect of the microbiota in HNSCC tumorigenesis and progression, the study of its potential role as a predictive immune biomarker is warranted. This review examines the available evidence on emerging immune predictive biomarkers of response to anti-PD-1/PD-L1 therapy in HNSCC, introducing the microbiota and its potential use as a predictive immune biomarker in this disease.
Detecting a Survival Benefit to Dose Escalation
Authors: Kaveh Zakeri, Brent S. Rose, Loren K. Mell
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal